Navigation Links
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
Date:12/8/2009

DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.

"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.

HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").

About Hemodynamic Therapeutics, Inc.

HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVenture
'/>"/>

SOURCE Hemodynamic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MINNEAPOLIS, Jan. 19, 2012 Zyga Technology, Inc. announced ... the company and will serve as Vice President of ... (Logo: http://photos.prnewswire.com/prnh/20110118/CG30384LOGO ) Joe ... Medical Device Industry.  He began his career at Codman ...
... Berkery Noyes, an independent middle market investment bank, today ... trend report for the Pharma & Healthcare ... report analyzes the sector for 2011 and compares it ... includes information and technology companies servicing pharmaceutical, healthcare payer, ...
Cached Medicine Technology:Zyga Technology, Inc. Makes Two Key Additions to the Sales Leadership Team 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 3
(Date:7/25/2014)... Tucson, AZ (PRWEB) July 25, 2014 ... Solutions , a Nuanced Media client and the ... medical and dental employee handbooks, announced their partnership ... , TransAct is a registered ISO/MSP of Chase ... in the transaction processing industry. Companies that are ...
(Date:7/25/2014)... This is a professional and in-depth ... (GOS) industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:7/25/2014)... 2014 Drexel University College of Medicine ... MS, FACP, has been appointed vice dean for education, effective ... from The Commonwealth Medical College, where she is currently chair ... affairs, and professor of medicine. , As a member ... Weber had a major role in many aspects of the ...
(Date:7/25/2014)... 24, 2014 (HealthDay News) -- Shift workers, especially men, may ... people not on such schedules, a new study suggests. ... on a set schedule, with shifts moving around at various ... all surprising," said one expert, Dr. Alan Manevitz, a clinical ... "Physicians have long known that working shifts disrupts many key ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay --, Treatment for lymphoma ... Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of ... who are still in their reproductive years. For men, ... production. Although most men regain their fertility within two ... be counseled about the possibility of this significant side ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, May ... preliminary, genetic test that seems to predict which breast cancer ... in turn, could greatly help guide treatment, according to a ... of the American Medical Association . The findings are ...
... , TUESDAY, May 10 (HealthDay News) -- Shortages of anesthetics ... of a new survey. The findings revealed that more ... 1,350 from the United States) are experiencing a shortage of ... percent of the respondents encountered a similar problem, the poll ...
... 10 (HealthDay News) -- Many tanning salons in the United ... cancer risks posed by tanning beds, according to a new ... more than 3,800 white females aged 14 to 22 from ... attitudes and behavior. The survey found that 43 percent ...
... About 14 percent of strokes happen while people are sleeping, ... the hospital in time for a potentially brain-saving treatment, a ... ischemic stroke must be given within a few hours after ... symptoms often can,t receive the treatment since we can,t determine ...
... the disturbing act of self-injury is nothing new to ... identified a more severe type of behavior that is ... and under-reported, Self-Embedding Behavior (SEB) is a form of ... tissue either under the skin or into muscle. ...
... the prevalence of overall cardiovascular risk in the Spanish working ... risk (8% on men and 2% in women). This prevalence ... the farming sector, followed by construction, industry and services. ... level of cardiovascular risk, but only a minority of these ...
Cached Medicine News:Health News:Genetic Test Shows Promise in Guiding Breast Cancer Care 2Health News:Genetic Test Shows Promise in Guiding Breast Cancer Care 3Health News:Shortage of Anesthetics Reported 2Health News:Too Few Teens Know the Dangers of Tanning Beds: Poll 2Health News:Research Suggests 1 in 7 Strokes Happens During Sleep 2Health News:A new study on self-injury behavior encourages quick and targeted intervention 2Health News:6 percent of Spanish workers have high cardiovascular risk 2
The Shandon Citadel is a low cost, reliable, time-tested carousel-type tissue processor with convenient touch key operation. The Citadel 2000 has 110 cassette capacity and the Citadel 1000 has a cap...
... Senior Grossing Wokrstation is a durable, ... for gross examination and sectioning of ... 3 efficient ventilation systems and options ... water faucets, table rinses, disposals and ...
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... Gross-Star Grossing Workbench is a durable, ... gross examination and sectioning of specimens. ... ventilation with a choice of 3 ... for cold/hot water faucet, optional formalin ...
Medicine Products: